Ovitrel (international nonproprietary name - horiogonadotropin alpha) belongs to a group of luteinizing funds. Speaking in plain language, this means that stimulate the ovaries of female sex hormones - estrogen. They are responsible and ovulation: the process, without which it would be fertilized, and hence the beginning of a new life.

Product form

 Packing drug Otrivel
 Ovitrel is available in two dosage forms:

  • solution for subcutaneous administration. In one syringe (for convenience, the solution is discharged directly into syringes) containing 0, 25, or 0 5 mg horiogonadotropina alpha, equivalent, respectively, 6,500 IU and 13,000 IU. The volume of the syringe is 0, 5 ml. The syringes are placed in a plastic container, packed in a cardboard box with the instructions to Ovitrelyu on the application;
  • lyophilizate powder (obtained by drying by sublimation substance) to prepare a solution for subcutaneous administration. One vial contains 0 to 25 mg of active ingredient. In addition to the vial in secondary packaging (carton) is embedded as a vial with a solvent, which acts as water for injection, and the instruction to Ovitrelyu for use. The box can be 1, 2 or 10 units with the drug substance and as many vials with the solvent;

Ovitrelya manufacturer is an Italian pharmaceutical company "Merck Serono".

Analogs Ovitrelya

For drugs, similar in composition to Ovitrelyu and currently registered in the State Register of medicines of Russia include the following drugs:

  • Chorionic Gonadotropin, Russia (lyophilisate);
  • Ekostimulin, Russia (lyophilisate);
  • Pregnil, Netherlands (lyophilisate);
  • Horagon, Germany (powder).

As this list of synonyms of drugs in a syringe in a ready-made solution is available only Ovitrel. Judging by the reviews of Ovitrele, this dosage form is very popular among consumers because It minimizes the number of manipulations of the preceding injection.

Pharmacological action

Horiogonadotropin alpha, synthesized by recombinant DNA technology is, in fact, a complete analog of human chorionic gonadotropin released the female placenta during pregnancy: the amino acids in it are arranged in the same sequence. Under its influence there is a rupture of follicles, that is, in other words, ovulation occurs. Besides horiogonadotropin alpha promotes the formation of the corpus luteum and initiates the production of progesterone and estradiol.

Indications Ovitrelya

According to the instructions on the application Ovitrelyu this drug is used in the following cases:

  • when superovulation (multiple follicle maturation) as a means of preparing "ground" for the use of assisted reproductive technologies, including in vitro fertilization (for daily use, the more common is the abbreviation ECO). The drug is used to stimulate the final stages of follicular maturation and corpus luteum formation;
  • during anovulatory (no ovulation) or oligoovulyatornom (irregular ovulation cycle) infertility for stimulation of oocyte maturation and the formation of the corpus luteum at the final stage of maturation of the follicles.

Regulations on the use of Ovitrelyu

Ovitrel for subcutaneous administration, the syringe should not be used more than once.

For the purposes of assisted reproductive technologies Ovitrel dose 0, 25 mg administered once after 24 or 48 hours after injection of luteinizing hormone or follicle, when the level of follicle reached optimum.

In the case of the introduction of the principle of infertility Ovitrelya the same with the only refinement: desirable sexual intercourse on the day of injection and the day after.

Terms of subcutaneous injections are detailed in the package insert (instructions for Ovitrelyu).


The mechanism of action and reviews Ovitrele caused the inclusion in the instructions the following contraindications:

  • tumors of the pituitary gland and the hypothalamus;
  • idiosyncrasy of the drug;
  • vaginal bleeding of unknown etiology;
  • Malignant tumors of the breast, uterus, ovary;
  • the period of time within three months after an ectopic pregnancy;
  • thrombotic occlusion of blood vessels, wherever located;
  • birth defects of the genital organs, excluding the possibility of pregnancy;
  • hysteromyoma, measures that prevent pregnancy;
  • postmenopausal stage of menopause.

side effect

In a review of Ovitrele recorded side effects of the drug such as:

  • pain at the injection site;
  • weakness, headache, fatigue;
  • mood swings, restlessness, depression;
  • dyspeptic symptoms (nausea, abdominal pain, diarrhea);
  • ovarian hyperstimulation syndrome (in the medical literature often abbreviated as OHSS);
  • breast tenderness on palpation.

Strictly speaking, the reviews Ovitrele regarding overdose with this drug available to clinicians, have been reported, but it is believed that it is a sign of ovarian hyperstimulation syndrome. A manifestation of this syndrome is the formation of large cavities in the ovaries - cysts, fluid accumulation in the abdominal cavity, vasomotor disturbances. In such cases, it is recommended to stop the introduction of the drug, and for at least 4 days to abstain from sexual contact (in extreme cases, use a condom) to normalize the condition of the body.


 The drug vials Otrivel
 Admission Ovitrelya - a very important event, and it must be prepared with great care. It should be for sure the cause of the impossibility of pregnancy, to assess all potential risks associated with its occurrence, paying particular attention to the signs of hypothyroidism, adrenocortical insufficiency, elevated prolactin, pituitary and hypothalamic tumors. After initiation of therapy should be closely observe the reaction of the ovaries, because during treatment due to mass Ovitrelem follicular maturation increases the risk of ovarian hyperstimulation syndrome. And the last - not the best companion of ovulation induction. To avoid ovarian hyperstimulation syndrome should undergo regular ultrasound examination and measure the level of estradiol in the blood (which is useful to do before treatment, for the presence of a doctor at the disposal of the control data).

Ovitrel sometimes cause insignificant increase in the activity of the thyroid gland.

Ovitrel, like the vast majority of hormones, released from pharmacies at the official prescribing, Kojima at all times is a recipe statutory forms (such a clarification is necessary, first of all, for doctors handing out their assignments on scraps of paper).

Instructions for storage Ovitrelyu

Ovitrel require any special storage conditions. First - a refrigerator, in which the temperature should be maintained between 2-8? C. Store this medication in the original packaging and make sure that in any case it was not freezing. However, there is a significant caveat: in 30 days Ovitrel retains its properties at temperatures up to 25? C, so if the injection of the drug is scheduled for this time period, then store it in the refrigerator is not required. If for some reason, the injection was not made, and the drug is not stored in the refrigerator for more than a month, it will be destroyed.

Shelf life is 2 years Ovitrelya.